Investor Presentaiton

Reported EBIT margin of 28% in Q3, reflecting mostly inflationary headwind on input costs. Significant negative currency impact in Q3 Q3 2022/23 EBIT margin development before special items (%) 30.1 -3.3 Reported EBIT margin Q3 21/221 0.8 28.4 0.3 -0.2 0.3 27.6 0.4 A Gross Δ margin Δ Admin- A R&D- Distribution- to-sales to-sales to-sales A Other operating items Reported EBIT margin Q3 22/231 1 Before special items income of DKK 28 million in Q3 2022/23 and special items expenses of 20mDKK in Q3 2021/22. 12 Currency EBIT margin effect Q3 22/23 (Constant Currencies)1 • • Q3 2022/23 highlights Gross margin was 66%, against 69% in Q3 last year Negative impact from: raw material price increases, higher energy costs, double-digit wage inflation in Hungary, and ramp-up costs in Costa Rica. Electricity price hedges of ~400 EUR/MWh (double from last year) took effect in January. Positive impact from: Atos Medical, price increases, country and product mix, operating leverage and efficiency savings, and transportation costs due to declining sea freight rates Significant negative FX impact on the gross margin of 70 bps Operating expenses in Q3 amounted to DKK 2,337 million. Operating expenses grew 2% from last year. Atos Medical contributed with DKK 284 million, including DKK 52 million in amortisation costs. Distribution-to-sales ratio was 31%, on par with last year Distribution costs were up 3% vs. last year, driven by increased sales & marketing activities and travel post COVID-19 and continued commercial investments (Interventional Urology, consumer and digital, Atos Medical) The admin-to-sales ratio was 4%, against 5% last year. The R&D-to- sales ratio was 4%, in line with last year EBIT before special items was DKK 1,686 million, a 4% decrease from last year. Reported EBIT margin before special items was 28% against 30% last year (negative FX impact of 80 bps) Coloplast

View entire presentation